ADVERTIMA
28.7.2020 09:02:08 CEST | Business Wire | Press release
Advertima , an emerging computer vision platform provider, today announces the close of a €15 million Series A investment round led by existing shareholder Swiss real estate company, Fortimo Group. Advertima empowers grocers and other retailers to create smart spaces that offer consumer-centric, frictionless and relevant in-store shopping experiences. The investment will enable the start-up to further develop their platform on a global scale and strengthen their position as a critical player in the wider ecosystem of the smart space environments.
Through computer vision, machine learning and artificial intelligence (AI), Advertima has created the ‘Human Data Layer’, which visually interprets human behaviour in physical spaces. By providing a real-time and easily accessible data stream, Advertima gives the ability for the smart spaces of the future to interact with people in a seamless and meaningful way.
The first sector that Advertima has set its sights on is grocery retail. In a fast-changing retail world that is quickly adapting to the impact of COVID-19, Advertima’s technology helps fast-track the evolution of grocery retailers. Advertima offers smart inventory management and autonomous checkout while also providing engaging and relevant content on smart digital screens throughout the in-store shopping journey of every customer. By making retail spaces smart, grocers maximise the efficiency of their stores, increase their revenues and generate greater returns per square meter.
In the near future, smart spaces will be ubiquitous and a part of the fabric of everyday life. Advertima plays a crucial role in the emerging smart retail ecosystem, powered by their Human Data Layer. Consumers are at the core of the evolution of smart spaces and will expect a living and working environment where interaction with technology is seamless and unnoticeable.
Advertima’s smart retail portfolio has been developed with Switzerland’s largest retailer, Migros and the international grocer SPAR. The technology is already being used by 14 companies across eight different countries.
“It is clear that the rapid digitalisation of our society is going to have an impact on consumer habits, especially in the retail sector,” says Fortimo Group Founder Remo Bienz. “ Advertima is at the cutting-edge of technology in the retail space. As a long-standing shareholder, we know how visionary their technology is, but also how it has been successfully adopted by major, global organisations and already generated significant revenues. We’re excited to be part of Advertima’s journey.”
“We’ll be investing €25 million in the further development of our smart retail solutions over the next two years. €10 million of this investment will be financed by our own revenues so this €15 million round is a crucial milestone to help us achieve our vision for how the world will look by 2030,” says Advertima Co-Founder and CEO Iman Nahvi. “We see a world where the physical and digital layers are merged to enhance our daily professional and private lives. Advertima’s Human Data Layer will be one of the irreplaceable components in this whole ecosystem of applications and technologies that will build the foundation of our future lives.”
“Since its founding in 2016, our Swiss start-up has had a global technology vision. This funding round brings our vision nearer to reality,” says Damir Bogdan, Advertima Seed Investor and President of the Board.
For more information read Advertima CEO’s blog post here: https://advertima.com/blog/detail/series-a-ceo-message/
-ENDS -
Notes to Editors:
About Advertima
Advertima is a 3D computer vision platform provider founded in 2016 and headquartered in St.Gallen, Switzerland. Advertima visually interprets human behaviour in the physical world, enabling smart spaces of the future to interact with people in seamless and meaningful ways. Their real-time and easily accessible data stream, called the ‘Human Data Layer’, powers their smart retail solutions, including Autonomous Store and Smart Signage. These next-generation solutions empower companies to create the customer experience of tomorrow: frictionless, relevant and highly-targeted. Advertima is fully compliant with the EU General Data Privacy Regulation (GDPR).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
